

**UNITED STATES DISTRICT COURT  
EASTERN DISTRICT OF LOUISIANA**

**IN RE: TAXOTERE (DOCETAXEL) ) MDL No. 16-2740**  
**PRODUCTS LIABILITY )**  
**LITIGATION ) SECTION: "H" (5)**  
)  
**This document relates to: )**  
Elizabeth Kahn, 16-17039 )

**ORDER AND REASONS**

Before the Court is a Motion for Reconsideration on Warnings Causation (Doc. 12536). On May 26, 2021, the Court held oral argument on the Motion. For the following reasons, the Motion is **DENIED**.

**BACKGROUND**

Plaintiffs in this multidistrict litigation ("MDL") are suing several pharmaceutical companies that manufactured and/or distributed a chemotherapy drug, Taxotere or docetaxel,<sup>1</sup> that Plaintiffs were administered for the treatment of breast cancer or other forms of cancer. Among these companies are Defendants sanofi-aventis U.S. LLC and Sanofi U.S. Services Inc. (collectively, "Sanofi" or "Defendants"). Plaintiffs allege that the drug caused permanent alopecia, or permanent hair loss. Plaintiffs bring claims of failure to warn, negligent misrepresentation, fraudulent misrepresentation, and more. The first bellwether trial was held in September 2019, and the second is set for August 23, 2021.<sup>2</sup>

Plaintiff Elizabeth Kahn is the designated plaintiff for the second bellwether trial. In its Order and Reasons dated April 7, 2020 (Doc. 9888) (the

---

<sup>1</sup> Docetaxel is the generic version of Taxotere.

<sup>2</sup> The second trial was continued due to the COVID-19 pandemic.

“Order”), the Court ruled on Sanofi’s Motion for Summary Judgment Based on Warnings Causation as to Kahn.<sup>3</sup> Applying the learned intermediary doctrine, the Court considered whether a different warning in the Taxotere label would have changed the prescribing decision of Kahn’s oncologist, Dr. Carl Kardinal. The Court considered whether Dr. Kardinal would have warned Kahn of a risk of permanent alopecia had he known of it, and the Court considered “how patient choice then would have steered the conversation and the ultimate prescribing decision.”<sup>4</sup> The Court cited testimony from Dr. Kardinal saying that he would have told Kahn of such a risk and would have discussed other options with her had she not wished to take Taxotere. Then, the Court cited testimony from Kahn saying that if she was told that Taxotere carried a risk of permanent hair loss, she would have asked about other options. Based on this, the Court found that there was a genuine issue of fact on causation.

In the instant Motion, Sanofi now asks the Court to reconsider its Order based on a recent Fifth Circuit decision. Plaintiff opposes the Motion.

### **LEGAL STANDARD**

A motion to reconsider an interlocutory order is governed by Federal Rule of Civil Procedure 54(b), which states that “any order or other decision, however designated, that adjudicates fewer than all the claims or the rights and liabilities of fewer than all the parties does not end the action as to any of the claims or parties and may be revised at any time before the entry of a judgment adjudicating all the claims and all the parties’ rights and liabilities.” “Under Rule 54(b), ‘the trial court is free to reconsider and reverse its decision

---

<sup>3</sup> The Court granted the Motion in part and dismissed Plaintiff’s redhibition claim. Sanofi seeks reconsideration only insofar as the Court denied the Motion.

<sup>4</sup> Doc. 9888 at 4.

for any reason it deems sufficient, even in the absence of new evidence or an intervening change in or clarification of the substantive law.”<sup>5</sup> “[T]he power to reconsider or modify interlocutory rulings is committed to the discretion of the district court, and that discretion is not cabined by the heightened standards for reconsideration governing final orders.”<sup>6</sup>

### LAW AND ANALYSIS

Sanofi argues that the Fifth Circuit has now established the causation standard relevant to this litigation. Sanofi avers that the dispositive question is whether the physician would have changed his prescribing decision had he been given a different warning, and Sanofi asserts that the Fifth Circuit rejected the notion that the inquiry should consider how patient choice would have steered the conversation between the patient and her doctor.

The Court finds no reason to reverse its original decision. As set forth in the Order at issue, under Louisiana law, failure to warn claims involving prescription drugs are subject to the learned intermediary doctrine.<sup>7</sup> Under the doctrine, the manufacturer of a prescription drug “has no duty to warn the patient, but need only warn the patient’s physician.”<sup>8</sup> In other words, a manufacturer’s duty runs only to the physician—the learned intermediary.<sup>9</sup>

The Fifth Circuit has held that there is a two-prong test governing inadequate warning claims under the Louisiana Products Liability Act (LPLA) when the learned intermediary doctrine is applicable:

---

<sup>5</sup> *Austin v. Kroger Texas, L.P.*, 864 F.3d 326, 336 (5th Cir. 2017) (quoting *Lavespere v. Niagara Mach. & Tool Works, Inc.*, 910 F.2d 167, 185 (5th Cir. 1990)).

<sup>6</sup> *Id.* (quoting *Saint Annes Dev. Co. v. Trabich*, 443 F. App’x 829, 831–32 (4th Cir. 2011)).

<sup>7</sup> *Grenier v. Med. Eng’g Corp.*, 99 F. Supp. 2d 759, 765 (W.D. La. 2000) (applying Louisiana law), *aff’d*, 243 F.3d 200 (5th Cir. 2001).

<sup>8</sup> *Willett v. Baxter Intern., Inc.*, 929 F.2d 1094, 1098 (5th Cir. 1991).

<sup>9</sup> *Grenier*, 99 F. Supp. 2d at 766.

First, the plaintiff must show that the defendant failed to warn (or inadequately warned) the physician of a risk associated with the product that was not otherwise known to the physician. Second, the plaintiff must show that this failure to warn the physician was both a cause in fact and the proximate cause of the plaintiff's injury.<sup>10</sup>

Regarding the second prong, the law is well established that, to prove causation, “the plaintiff must show that a proper warning would have changed the decision of the treating physician, i.e. that but for the inadequate warning, the treating physician would not have used or prescribed the product.”<sup>11</sup>

As Sanofi notes, the Fifth Circuit recently issued a ruling relating to a case in this MDL—*June Phillips v. Sanofi U.S. Services, et al.*<sup>12</sup> Applying the learned intermediary doctrine in the chemotherapy context, the court noted that while “[t]he decision to use a drug in a particular circumstance rests with [both] the doctor and the patient,”<sup>13</sup> a causation analysis must focus on “the prescribing physician’s decision to prescribe the drug.”<sup>14</sup> The court wrote:

[T]o the extent that patient choice is relevant, that relevance is cabined to helping us decide whether [the plaintiff’s] evidence—including that of other available treatments and the importance she places on her appearance—is sufficient to introduce a genuine dispute of material fact as to whether [the physician’s]

<sup>10</sup> *Stahl v. Novartis Pharmaceuticals Corp.*, 283 F.3d 254, 265–66 (5th Cir. 2002) (internal citation omitted).

<sup>11</sup> *Willett*, 929 F.2d at 1099. *See also* *Pellegrin v. C.R. Bard*, 2018 WL 3046570, at \*4 (E.D. La. June 20, 2018).

<sup>12</sup> *In re Taxotere (Docetaxel) Prods. Liab. Litig. (June Phillips v. Sanofi U.S. Services, et al.)*, No. 20-30405, 2021 WL 1526429 (5th Cir. Apr. 19, 2021).

<sup>13</sup> *Id.* at \*3 (quoting *Calhoun v. Hoffman-La Roche, Inc.*, 768 So. 2d 57, 59 n.1 (La. App. 1 Cir. 2000), *writ denied*, 765 So. 2d 1041 (La. 2000)).

<sup>14</sup> *Id.* The Court acknowledges the clarification from the Fifth Circuit in Footnote 4 of its opinion, providing that the question is not “whether and how the doctor would have advised the patient of the risk of permanent alopecia associated with Taxotere, whether the patient would have inquired about other options, what the doctor would have recommended, and what decision the plaintiff would have ultimately made.” *Id.* at \*3 n.4.

prescribing decision would have been different had *he* known that Taxotere’s associated risk of alopecia was potentially permanent rather than temporary.<sup>15</sup>

Against this backdrop, the Fifth Circuit considered the facts before it.

First, the court considered whether a warning regarding permanent alopecia would have altered the physician’s risk-benefit assessment of Taxotere or his opinion that Taxotere was the best treatment for Phillips, the plaintiff.<sup>16</sup> The court answered no to both.<sup>17</sup> Next, the court considered whether there was any evidence that the plaintiff “might have steered the conversation in such a way that [her oncologist] would have changed his prescribing decision had he known that the risk of alopecia associated with Taxotere was potentially permanent rather than temporary.”<sup>18</sup> The court found “no indication that [the plaintiff] investigated or asked about alternatives that might avoid the abnormal hair growth or hair loss.”<sup>19</sup> Instead, the court found that the plaintiff “put her faith in [her physician],’ and consented to treatment.”<sup>20</sup> Finding insufficient evidence to create an issue of fact on causation, the court affirmed summary judgment for Sanofi.<sup>21</sup>

With this guidance in mind, the Court now turns to Plaintiff’s oncologist, Dr. Kardinal. Like the oncologist in *Phillips*, Dr. Kardinal testified that if the Taxotere label had warned of permanent alopecia, this would not have changed his chemotherapy recommendation for Plaintiff Kahn.<sup>22</sup> He testified, however, that such a risk “would have to be included in the discussion” with a patient.<sup>23</sup>

---

<sup>15</sup> *Id.*

<sup>16</sup> *See id.* at \*4.

<sup>17</sup> *See id.*

<sup>18</sup> *Id.* at \*4.

<sup>19</sup> *Id.*

<sup>20</sup> *Id.*

<sup>21</sup> *See id.* at \*5.

<sup>22</sup> Doc. 9300-9 at 15.

<sup>23</sup> Doc. 9422-4 at 13.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.